News
Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths
The agency also revoked Sarepta's platform technology designation for AAVrh74 Friday and issued a safety communication saying the agency was investigating the three deaths due to acute liver failure following treatment with Sarepta's AAVrh74 gene therapies.
MedPage Today on MSN11h
Gene Therapy May Hold Better Outcomes for Congenital Deafness Than Cochlear Implant
Youth with congenital deafness treated with gene therapy showed better progress on certain hearing measures than counterparts ...
Sarepta Therapeutics said on Monday that it will pause all shipments of its Elevidys gene therapy in the United States after a muscular dystrophy patient who received a different, experimental ...
Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.
A team of Chinese medical experts say they can produce anti-cancer cells directly inside the human body using gene therapy ...
Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...
Our Bureau, Mumbai Friday, July 18, 2025, 17:45 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback